Shares of Enfusion, Inc. (NYSE:ENFN – Get Rating) traded down 6.2% during mid-day trading on Monday . The company traded as low as $7.85 and last traded at $7.88. 5,323 shares were traded during mid-day trading, a decline of 98% from the average session volume of 276,447 shares. The stock had previously closed at $8.40.
A number of equities analysts have issued reports on the stock. The Goldman Sachs Group decreased their price objective on shares of Enfusion from $24.00 to $15.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 16th. Morgan Stanley reduced their price target on shares of Enfusion from $22.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Friday, March 25th. Stifel Nicolaus reduced their price target on shares of Enfusion from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, March 21st. Zacks Investment Research downgraded shares of Enfusion from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. Finally, Credit Suisse Group dropped their target price on shares of Enfusion from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, March 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.67.
The stock’s 50-day moving average is $12.53 and its two-hundred day moving average is $16.00.
Institutional investors have recently modified their holdings of the stock. Dragoneer Investment Group LLC raised its position in Enfusion by 1.1% in the first quarter. Dragoneer Investment Group LLC now owns 6,490,000 shares of the company’s stock worth $82,553,000 after acquiring an additional 67,779 shares during the period. Hhlr Advisors LTD. bought a new position in Enfusion in the fourth quarter worth approximately $104,180,000. Alliancebernstein L.P. bought a new position in Enfusion in the fourth quarter worth approximately $48,717,000. TimesSquare Capital Management LLC raised its position in Enfusion by 8.8% in the first quarter. TimesSquare Capital Management LLC now owns 1,631,305 shares of the company’s stock worth $20,750,000 after acquiring an additional 131,280 shares during the period. Finally, BlackRock Inc. raised its position in Enfusion by 3.9% in the first quarter. BlackRock Inc. now owns 1,342,703 shares of the company’s stock worth $17,079,000 after acquiring an additional 49,953 shares during the period. Institutional investors own 61.18% of the company’s stock.
About Enfusion (NYSE:ENFN)
Enfusion Inc offers software-as-a-service for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
- Get a free copy of the StockNews.com research report on Enfusion (ENFN)
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.